Baxter International Inc.
Every calculator, already run for BAX
Open the full toolkit →You have the numbers on BAX. Get the argument.
A written report on which of these readings actually decide the outcome for Baxter International Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
13 analysts covering BAXAnalyst Price Target Disagreement for Baxter International Inc.
Wall Street's bull case implies +68% from the current price; the bear case implies -3%. A 71% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for BAX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision po…
BAX — frequently asked
Is BAX a buy right now?
Wall Street's consensus rating on Baxter International Inc. is Hold across 13 analysts, with a mean price target of $28.73 (+21% vs. the current $23.80). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is BAX overvalued?
BAX trades at — trailing earnings, against a DCF fair value of $75 per share. The current price implies -8% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is BAX's next earnings date?
Baxter International Inc. is next scheduled to report earnings around Oct 29, 2026. A full BAX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Baxter International Inc.?
Analysts covering Baxter International Inc. (BAX) range from a bear-case target of $23.00 to a bull-case high of $40.00, with a mean consensus target of $28.73 across 11 analysts. The spread of $17.00 (71% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Baxter International Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Baxter International Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BAX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Baxter International Inc., in minutes. 3 free reports included with every account — no credit card required.